RE: Morning all !31 Oct 2023 07:48
Operating loss down to £11.9 from £13.3 million. CEO - "Revenue from the licencing deal with Genmab of £5.3 million reduced the operating loss significantly."
In the Chairman's words, "Remarkable initial data from 11 patients showed an 82% objective response rate (ORR) to treatment with no increase in toxicity, better than 70% ORR that the trial was configured to show. We are excited because, to our knowledge, no other combination has achieved this response rate with doublet checkpoint inhibitors in unresectable metastatic melanoma. Confirmation of this data in a larger cohort could make a significant impact on melanoma patient survival, especially as melanoma is now the most common cancer in young women and is increasing in incidence."
MMmmm REMARKABLE!
J-M C again, "We believe the impressive data from the SCOPE trial, combined with further near-term milestones and commercial opportunities will soon provide exciting inflection drivers." Inflection DRIVERS eh? More than one inflection point!
I couldn't see thanks being proffered to BDO for making the deadline in difficult circumstances LOL but at least the alarmed can take comfort from this, "The auditors issued an unqualified audit opinion which did not contain any statement under section 498(2) or 498(3) of the Companies Act 2006." As discussed, the 'delay' was never because of a problem within Scancell itself.
Perhaps we'll be told soon when the previously planned Q & A for Investors and Analysts will be taking place.
Back to normal then - just waiting for data and deals GLA
Sign In
Follow the stocks
